Results 121 to 130 of about 941,442 (284)

Tumor suppressor and hepatocellular carcinoma

, 2008
A few signaling pathways are driving the growth of hepatocellular carcinoma. Each of these pathways possesses negative regulators. These enzymes, which normally suppress unchecked cell proliferation, are circumvented in the oncogenic process, either the ...
Martin, Juliette, Dufour, Jean-François
core   +1 more source

LRG1 Drives Pathological Angiogenesis by Disrupting Neutrophil Mitochondrial Homeostasis in Bladder Cancer

Advanced Science, EarlyView.
In bladder cancer, LRG1 binds to ANXA2 to trigger mitochondrial ROS‐dependent NETosis. This pathogenic cascade actively uncouples endothelial‐mural cell interactions, driving profound vascular destabilization. Consequently, targeting the LRG1‐ANXA2 axis attenuates the neutrophil burden and induces structural vascular normalization, offering a powerful ...
Dongshan Chen, Cong Zhang, Song Xue, Yuan Zeng, Haochen Cui, Chenfei Wang, Jiayi Feng, Lei Yan, Yuanwei Zang   +8 more
wiley   +1 more source

A Programmable Calcification Nanoplatform for Loco‐Regional Calcification‐Immune Hepatocellular Carcinoma Therapy

Advanced Science, EarlyView.
An in situ‐grown BP‐CaO2 nanoplatform supplies coordinated Ca2+, endogenous phosphate, and oxidative stress to convert tumor calcification from a passive endpoint into an active immune‐remodeling process. Widespread hydroxyapatite deposition is visualized by CT, while multi‐omics reveals MCOLN2 as a calcium‐responsive mediator linking biomineralization
Long Liu, Peng Li, Zhixiang Lu, Shuqin Xu, Juanjuan Wang, Kai Ma, Haodong Yu, Can Zhou, Hu Chen, Gang Liu, Yi Lyu, Shuang Bai   +11 more
wiley   +1 more source

HCC-Check: A Novel Diagnostic Tool for Early Detection of Hepatocellular Carcinoma Based on Cytokeratin-1 and Epithelial Membrane Antigen: A Cross-Sectional Study

Technology in Cancer Research & Treatment
Background: Hepatocellular carcinoma is frequently diagnosed in advanced stages, leading to a poorer prognosis. Therefore, early diagnosis and identification of biomarkers may significantly improve outcomes.
Kareem A. Attallah MSc, Mohamed S. Albannan PhD, Khaled Farid MD, PhD, Sherine M. Rizk PhD, Nevine Fathy PhD   +4 more
doaj   +1 more source

Hepatocellular carcinoma: epidemiology and risk factors

, 2014
Michael C Kew Department of Medicine, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa Abstract: Hepatocellular carcinoma is one of the major malignant tumors in the world today.
Kew MC
core  

Chronic HBV Infection Disrupts CCL5‐Secreting cNK Cells and Attenuates Liver Accumulation and Activation of DCs and HBV‐Specific T Cells

Advanced Science, EarlyView.
ADORA2A activation suppresses NFκB‐dependent CCL5 production in cNK cells during chronic HBV infection, disrupting intrahepatic DC recruitment and HBV‐specific CD8+ T‐cell differentiation and function. Targeting the ADORA2A/NFκB/CCL5 axis restores antiviral immunity and facilitates HBV clearance.
Ailu Yang, Yucan Wang, Yating Yu, Jing Wu, Cuiping Bao, Zixuan Wang, Qiuju Han, Zhigang Tian, Jian Zhang, Huajun Zhao   +9 more
wiley   +1 more source

Hsa-miR-423-5p selectively loaded in hypoxic exosomes reduces the sensitivity of normoxic hepatocellular carcinoma to sorafenib via autophagy

Cancer Cell International
Background For patients with advanced hepatocellular carcinoma, sorafenib is considered a highly effective targeted molecular drug; however, sorafenib resistance limits its therapeutic efficacy.
Bian Shu, Min Zou, Rui Liao, Diguang Wen, Xianzhi Gao, Jiao Lu, Hua Song, Ziyi Sheng, Zuojin Liu, Yu You   +9 more
doaj   +1 more source

Engineering‐Modulated Molybdenum Enzymes Strategy for Tumor‐Specific Metabolic‐Immunotherapy

Advanced Science, EarlyView.
Biodegradable molybdenum sulfide nanoparticles were synthesized via a one‐pot strategy to increase molybdenum enzyme activity and thus effectively potentiate anti‐tumor immunity by integrating molybdenum‐based metalloimmunotherapy with hydrogen sulfide gas therapy.
Xiaoxiao Pan, Zifan Pei, Jie Wu, Nan Jiang, Qian Li, Yuqi Yang, Jie Cao, Yechen Huang, Shumin Sun, Qialu Du, Zhicheng Liu, Lin Zhang, Fei Gong, Jinhua Zhou, Liang Cheng   +14 more
wiley   +1 more source

Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights

, 2023
James Yu,1 Robin Park,1 Richard Kim2 1Division of Hematology and Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 2Department of Gastrointestinal Oncology, H.
Kim R, Yu J, Park R
core  

Genetic Ablation and Multi‐Omics Profiling Reveal CEP55 as a Key Driver of Tumorigenesis in Diverse Cancer Models

Advanced Science, EarlyView.
Genetic ablation of Cep55 in Pten‐deficient mouse models delays tumorigenesis. Integrated multi‐omics analyses (proteomics, phosphoproteomics, and spatial transcriptomics) reveal that CEP55 regulates oncogenic signaling (RAS/ERK, PI3K/AKT), integrin/FAK‐mediated adhesion, extracellular matrix (ECM) remodeling, and endocytosis.
Behnam Rashidieh, Yuanhao Yang, Amanda Louise Bain, Phillip Theron, Catharina Vosloo, Sahar Keshvari, Parinaz Ahangar, Brydie Bowden, Simon M. Tria, Ben B. Wang, Sandra Isenmann, Nicholas J. Westra van Holthe, Zherui Xiong, Hani Vu, Sowmya Sharma, Asmerom Sengal, J. Alejandro Lopez, John Finnie, Antonella Papa, Pascal H.G. Duijf, Quan Nguyen, Pirjo M. Apaja, Kum Kum Khanna   +22 more
wiley   +1 more source